Ipca Labs (Large Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Ipca Laboratories Limited |
|||
|
Price: ₹1,582.50 | ||
| 52 Week Low: ₹1,041.00 52 Week High: ₹1,708.65 |
|||
| Market Capital: 39,949.62 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Ipca Labs Share Price Target For 2024
- 1.1.1: Ipca Labs Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Ipca Labs Share Price Target For 2025
- 1.2.1: Ipca Labs Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Ipca Labs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Ipca Labs Brief Company Overview
- 4: Ipca Labs Financial Performance
- 4.0.1: Is Ipca Labs A Good Buy For Long Term?
To predict the Ipca Labs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Ipca Labs Share Price Target For 2024
The line chart displays the monthly closing prices of Ipca Labs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Ipca Labs shares in 2024, see the table below.
Ipca Labs Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1650.83 (+4.31%) | Fibonacci Extension Level 123.60% |
| 2024 Target 2 | 1624.02 (+2.62%) | Price Action: Chart |
| 2024 Target 1 | 1607.94 (+1.60%) | Price Action: 28 Oct 2024 High |
| Current Price | 1582.50 | Ipca Labs's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1573.9 (-0.55%) | Price Action: 27 Nov 2024 High |
| Stop Loss 2 | 1558.0 (-1.55%) | Price Action: 26 Nov 2024 Low |
| Stop Loss 3 | 1542.15 (-2.55%) | Price Action: 06 Dec 2024 High |
Short-Term Technical Outlook
Current Technical Position: Ipca Labs is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹1572.18 serves as the nearest technical reference point.
Historical Returns: 3-month: +5.77% | 6-month: +40.48% | 1-year: +42.57%
Ipca Labs Share Price Target For 2025
The line chart displays the monthly closing prices of Ipca Labs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Ipca Labs shares in 2025, see the table below.
Ipca Labs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2079.43 (+31.40%) | Price Action: Chart |
| 2025 Target 2 | 2040.66 (+28.95%) | Fibonacci Extension Level 150.00% |
| 2025 Target 1 | 2018.85 (+27.57%) | Fibonacci Extension Level 64.90% |
| Current Price | 1582.50 | Ipca Labs's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1478.5 (-6.58%) | Price Action: 19 Dec 2024 Low |
| Stop Loss 2 | 1451.24 (-8.30%) | Price Action: Oct 2024 Low |
| Stop Loss 3 | 1425.99 (-9.90%) | Price Action: Aug 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Ipca Labs is currently trading near its 52-week high of ₹1708.65, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +42.57% | 3-year: +47.44% | 5-year: +184.37%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Ipca Labs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,582.50 | ||
| 2024 | ₹1,699.28 | +7.38% | ₹1,724.77 |
| 2025 | ₹2,326.88 | +36.93% | ₹2,361.78 |
| 2026 | ₹2,759.22 | +18.58% | ₹2,800.61 |
| 2027 | ₹3,334.58 | +20.85% | ₹3,384.60 |
| 2028 | ₹3,968.34 | +19.01% | ₹4,027.87 |
| 2029 | ₹4,698.25 | +18.39% | ₹4,768.72 |
| 2030 | ₹5,362.12 | +14.13% | ₹5,442.55 |
| 2031 | ₹5,613.71 | +4.69% | ₹5,697.92 |
| 2032 | ₹6,192.90 | +10.32% | ₹6,285.79 |
| 2033 | ₹6,872.11 | +10.97% | ₹6,975.19 |
| 2034 | ₹7,697.23 | +12.01% | ₹7,812.69 |
| 2035 | ₹8,397.35 | +9.10% | ₹8,523.31 |
| 2036 | ₹8,468.21 | +0.84% | ₹8,595.23 |
| 2037 | ₹9,051.22 | +6.88% | ₹9,196.71 |
| 2038 | ₹9,775.87 | +8.01% | ₹9,946.46 |
| 2039 | ₹10,578.14 | +8.21% | ₹10,736.81 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Ipca Labs Brief Company Overview
**Company Overview** Established in 1949, Ipca Laboratories is a leading pharmaceutical company in India. They manufacture and market pharmaceutical formulations and active pharmaceutical ingredients (APIs) for diverse therapeutic segments. **Key Products and...
Services** Ipca's product portfolio includes: Generic and branded formulations APIs in areas like anti-hypertensive, anti-malarial, and anti-diabetic **Diverse Product Range** Their therapeutic segments cover a wide range, including: Allergy Cardiology Neurology Ophthalmology Respiratory diseases **Reputation and Commitment** Ipca Laboratories has a strong reputation in the industry for its commitment to quality and innovation.Ipca Labs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 39,949.62 Crore | Market valuation of Ipca Labs's shares. |
| Revenue (TTM) | 8,213.3 Crore | Total revenue generated by Ipca Labs over the past twelve months. |
| Net Income (TTM) | +5,767,699,968.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +14.04% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +7.02% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+31.80% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+18.09% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
18.61 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1,438.35 Crore | Sum of Ipca Labs's current & long-term financial obligations. |
| Total Cash | 854.26 Crore | Total amount of liquid funds available to Ipca Labs. |
| Beta | 0.22 | Beta is less than 1 indicating that the Ipca Labs's price is less volatile than the market. |
Is Ipca Labs A Good Buy For Long Term?
Ipca Labs, a large-cap stock with a market capitalization of ₹39,949.62 crore, shows strong growth potential. While its Q2 2024-25 report reveals debt of ₹1,438.35 crore against a cash balance of ₹854.26 crore, impressive revenue growth of 31.8% quarter-over-quarter and a 61.76% return over the past 12 months are positive indicators. The 7.02% profit margin, however, needs improvement. Considering its robust past performance (45.40% return in 3 years, 296.79% in 5 years) and recent strong returns, Ipca Labs is a good buy for the long term, but ongoing monitoring of debt levels is crucial.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
